» Articles » PMID: 12598445

How Big is the Burden of Visual Loss Caused by Age Related Macular Degeneration in the United Kingdom?

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 2003 Feb 25
PMID 12598445
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To predict the burden of blindness, partial sight, and visual impairment (binocular visual acuity 6/18 or less) due to late stage age related macular degeneration (AMD) in the ageing population of the United Kingdom.

Methods: A systematic review, followed by a request for data, was used to establish a pooled prevalence of AMD and corresponding visual loss. Prevalence figures were applied to the UK population. Using UK population trends, the future burden of AMD over the coming decade was established.

Results: Pooled data from six studies showed that the prevalence of visual loss caused by AMD increased exponentially from the age of 70-85 years of age, with 3.5% (95% CI 3.0 to 4.1) having visual impairment beyond the age of 75 years. The authors estimate that there are currently 214 000 (95% CI 151 000 to 310 000) with visual impairment caused by AMD (suitable for registration). This number is expected to increase to 239 000 (95% CI 168 000 to 346 000) by the year 2011. Currently there are 172 000 (95% CI 106 000 to 279 000) and 245 000 (95% CI 163 000 to 364 000) with geographical and neovascular AMD, respectively.

Conclusions: Estimates of visual impairment agree with official statistics for the number registered partially sighted or blind, caused by AMD, and are well below other figures often cited. Although these estimates are associated with wide confidence intervals (CI) and a number of caveats, they represent the best available data, which can be used to guide health and social care provision for older people in the UK setting. Implications for low vision services are outlined.

Citing Articles

Neoteric Role of Quercetin in Visual Disorders.

Khil N, Sharma S, Sharma P, Alam M Curr Drug Res Rev. 2023; 16(2):164-174.

PMID: 37608659 DOI: 10.2174/2589977515666230822114324.


Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults.

Singh S, Keller P, Busija L, McMillan P, Makrai E, Lawrenson J Cochrane Database Syst Rev. 2023; 8:CD013244.

PMID: 37593770 PMC: 10436683. DOI: 10.1002/14651858.CD013244.pub2.


Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.

Mollan S, Fu D, Chuo C, Gannon J, Lee W, Hopkins J Br J Ophthalmol. 2021; 107(2):267-274.

PMID: 34518162 PMC: 9887382. DOI: 10.1136/bjophthalmol-2021-319383.


Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Hykin P, Prevost A, Sivaprasad S, Vasconcelos J, Murphy C, Kelly J Health Technol Assess. 2021; 25(38):1-196.

PMID: 34132192 PMC: 8287375. DOI: 10.3310/hta25380.


Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function.

Cerniauskas E, Kurzawa-Akanbi M, Xie L, Hallam D, Moya-Molina M, White K Stem Cells Transl Med. 2020; 9(12):1585-1603.

PMID: 32815311 PMC: 7695639. DOI: 10.1002/sctm.20-0211.


References
1.
Bird A, Bressler N, Bressler S, Chisholm I, Coscas G, Davis M . An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995; 39(5):367-74. DOI: 10.1016/s0039-6257(05)80092-x. View

2.
Balatsoukas D, Sioulis C, Parisi A, Millar G . Visual handicap in south-east Scotland. J R Coll Surg Edinb. 1995; 40(1):49-51. View

3.
Rovner B, Zisselman P . Depression and disability in older people with impaired vision: a follow-up study. J Am Geriatr Soc. 1996; 44(2):181-4. DOI: 10.1111/j.1532-5415.1996.tb02436.x. View

4.
VINDING T . Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmol Scand Suppl. 1995; (217):1-32. View

5.
Vingerling J, Klaver C, Hofman A, de Jong P . Epidemiology of age-related maculopathy. Epidemiol Rev. 1995; 17(2):347-60. DOI: 10.1093/oxfordjournals.epirev.a036198. View